Halozyme Therapeutics (HALO) News Today $54.43 +0.01 (+0.02%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$54.46 +0.04 (+0.06%) As of 05/28/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HALO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Implied Volatility Surging for Halozyme Therapeutics Stock OptionsMay 29 at 12:18 AM | msn.comHigh Growth Tech Stocks To Watch In The US May 2025May 29 at 12:18 AM | uk.finance.yahoo.comWhat's Driving the Market Sentiment Around Halozyme Therapeutics?May 29 at 12:18 AM | benzinga.comHalozyme to Participate at Upcoming Investor ConferencesMay 28 at 4:18 PM | prnewswire.comHalozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor IndicationsMay 28 at 8:30 AM | prnewswire.comArmis Advisers LLC Invests $295,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Armis Advisers LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,177 shares of the biopharmaceutical company's stock, valued at approximately $295,000. OtMay 28 at 5:45 AM | marketbeat.comTwo Sigma Investments LP Has $11.81 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Two Sigma Investments LP boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 403.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 247,030 shares of the bioMay 26 at 4:25 AM | marketbeat.comNovem Group Invests $841,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Novem Group purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 17,586 shares of the biopharmaceutical company's stock, valued at approMay 24, 2025 | marketbeat.comProShare Advisors LLC Buys 10,531 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)ProShare Advisors LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,114 shares of the biopharmaceutical company's stoMay 23, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $61.90 Consensus PT from AnalystsMay 21, 2025 | americanbankingnews.comSteamboat Capital Partners LLC Buys 75,890 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Steamboat Capital Partners LLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 43.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 249,751 shares of the biopMay 20, 2025 | marketbeat.comNuveen Asset Management LLC Sells 8,634 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Nuveen Asset Management LLC lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,530,519 shareMay 20, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by BrokeragesHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been assigned a consensus rating of "Hold" from the twelve brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating andMay 20, 2025 | marketbeat.comRafferty Asset Management LLC Increases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Rafferty Asset Management LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 219,392 shares of the biopharmaceutical company'May 19, 2025 | marketbeat.comPoint72 Europe London LLP Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Point72 Europe London LLP bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 29,335 shares of the biopharmaceutical company's stock, valued at approximatMay 18, 2025 | marketbeat.comRedwood Investments LLC Has $1.54 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Redwood Investments LLC decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 34.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,189 sharesMay 17, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Stock Rating Lowered by Leerink PartnrsLeerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday.May 17, 2025 | marketbeat.comJanus Henderson Group PLC Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Janus Henderson Group PLC increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 702,085 shares of the biopharmaceutical company's stock after purchasing an additional 156,912 shMay 17, 2025 | marketbeat.comPanoramic Capital LLC Makes New $2.62 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Panoramic Capital LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 54,821 shares of the biopharmaceutical company's stock,May 16, 2025 | marketbeat.comCaptrust Financial Advisors Grows Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Captrust Financial Advisors increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 24.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,862 shareMay 16, 2025 | marketbeat.comWhy Halozyme Therapeutics, Inc. (HALO) Declined on TuesdayMay 15, 2025 | insidermonkey.comMorgan Stanley Downgrades Halozyme Therapeutics (HALO)May 15, 2025 | msn.comHalozyme Therapeutics (NASDAQ:HALO) Cut to Underperform at Leerink PartnersLeerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a report on Tuesday.May 15, 2025 | marketbeat.comHalozyme downgraded at Morgan Stanley on price control riskMay 14, 2025 | msn.comIs Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now?May 14, 2025 | finance.yahoo.comLeerink Partners Downgrades Halozyme Therapeutics (HALO)May 14, 2025 | msn.comHalozyme shares tumble on downgrade and CMS draft guidanceMay 13, 2025 | in.investing.comJ&J, Halozyme cut at Leerink on price control risk for combo productsMay 13, 2025 | msn.comHalozyme Therapeutics (HALO) Downgraded Amid Medicare Negotiation ConcernsMay 13, 2025 | gurufocus.comTop Biotech Halozyme Undercuts Its Breakout On Bad Medicare NewsMay 13, 2025 | investors.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 171.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 831,414 shares of the biopharmaceutical company's stock afterMay 13, 2025 | marketbeat.comAlgert Global LLC Acquires New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Algert Global LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 10,900 shares of the biopharmaceutical company's stock, valuedMay 13, 2025 | marketbeat.comIs Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now?May 12, 2025 | msn.comHalozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper MoatMay 12, 2025 | seekingalpha.comCoreCap Advisors LLC Increases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)CoreCap Advisors LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 36.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,831 shares of the biopharmaceutical company's stock after purMay 12, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Downgraded by Benchmark to "Hold"Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday.May 11, 2025 | marketbeat.comClark Capital Management Group Inc. Has $8.55 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Clark Capital Management Group Inc. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 30.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 178,827 shares of the biopharmaceutical compMay 11, 2025 | marketbeat.comCentiva Capital LP Takes $643,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Centiva Capital LP purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,450 shares of the biopharmacMay 11, 2025 | marketbeat.comS&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy PointsMay 10, 2025 | investors.comBrevan Howard Capital Management LP Invests $1 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Brevan Howard Capital Management LP purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,996 shares of theMay 10, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comHalozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High After Earnings BeatHalozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High on Better-Than-Expected EarningsMay 9, 2025 | marketbeat.comWells Fargo & Company Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $65.00Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday.May 9, 2025 | marketbeat.comAxa S.A. Purchases 23,835 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Axa S.A. increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 22.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,891 shares of the biopharmaceMay 9, 2025 | marketbeat.comStifel Financial Corp Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Stifel Financial Corp raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 79.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,768 shares of the biopharmaceutical company's stocMay 9, 2025 | marketbeat.comHalozyme Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 8, 2025 | finance.yahoo.comCary Street Partners Financial LLC Invests $4.74 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Cary Street Partners Financial LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 99,154 shares of the biopharmaceutMay 8, 2025 | marketbeat.comMarshall Wace LLP Invests $212,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,426 shares of the biopharmaceutical company's stMay 8, 2025 | marketbeat.comWhy Halozyme Therapeutics, Inc. (HALO) Skyrocketed On WednesdayMay 8, 2025 | msn.comInsights into Halozyme Therapeutics's Upcoming EarningsMay 7, 2025 | nasdaq.com Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼1.060.87▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼711▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today INCY News Today NBIX News Today EXEL News Today BMRN News Today EXAS News Today RGEN News Today MDGL News Today IONS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
